Category: Entrepreneurship


HBM Pharma/Biotech M&A and New Drug Approvals Reports 
Posted on Mar 15, 2016

  We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms

Licensing or Acquiring Assets from Big Pharma 
Posted on Aug 12, 2015

  Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike’s perspective is unique in that he has managed to pull this off not once, but twice. It has been our experience that doing this once is incredibly difficult. But why? Mike gives a few

Employee-Free Biotechs: A Virtual Panacea? 
Posted on Apr 13, 2015

  Last week Reuters published an article summarizing the “virtual” biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this model as far back as 2011. According to Reuters, The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously

Postcards from Trondheim 
Posted on Mar 23, 2015

  I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped teach a class on biotech entrepreneurism, and participated in various internal meetings and discussions with my Ventac Partners colleagues. Sitting in my office in New

The Keys to the Kingdom 
Posted on Mar 02, 2015

  There is a terrific article in Nature Biotechnology entitled Keys to the Kingdom. The article discusses a number of issues bioentrepreneurs may encounter when trying to license technology from a University. Most interesting are the differences between UK and US universities, especially with respect to equity distribution / division between the University and the remaining

Venture Funding of Therapeutic Innovation: An Important Report 
Posted on Feb 11, 2015

  Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by therapeutic area, by NCE vs. reformulation, and over time. Bruce Booth has a nice summary here, and you can download the report from here. BIO

Finally, Some Sense 
Posted on Jan 22, 2015

Today, Bruce Booth published yet another terrific post, where he discusses the current biotech investment bubble from the private word of venture backed biotechs (and, he puts many mainstream journalists to shame with this analysis). We think one of the more interesting insights in the post is this one, One would think with a big spike

The Life Sciences in Wyoming – Part Two of Three 
Posted on Nov 07, 2014

There’s more to Wyoming than this.  In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part Two of this series, Dr. Lindemann highlights some of the life science companies which are already operating in Wyoming. The concept of a state or region

The Life Sciences in Wyoming – Part One of Three 
Posted on Oct 30, 2014

 Is this the next major biotech cluster in the US? Wyoming? Yes, Wyoming. Why not? In the First of a Three-part series, our guest blogger Dr. Garrett Lindemann (@WyomingScience) discusses the growing life sciences industry in the State of Wyoming. All states in the US would love to have a bubbling life science industry like Massachusetts

Factors for successful virtual medtech 
Posted on Jul 06, 2012

Our good friend Raman Minhas at ATPBio has a really good post today on the critical factors for a medtech company to be successful using a virtual organizational model. Raman’s critical factors, with our comments, are: The Team –  In Raman’s case study, he notes that the founders had a tremendous network to tap into.

Burrill Speaks, We Agree 
Posted on Feb 21, 2012

The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It’s an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes an interesting point several times in the interview that are worth repeating: Let’s not just assume that we will always be going through a lengthy

AAPS: Impressions and Observations 
Posted on Oct 27, 2011

Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in DC to talk pharmaceutical science, especially formulation development, translational research, pharmacokinetics, and manufacturing. As the name suggests, AAPS is a science-driven conference. Thus, the tone

Incubating a biotech future for tomorrow 
Posted on Aug 22, 2011

On the one hand, you hate to see talent leaving the US. But, you have to applaud their attitude: “Although we are comfortable in America, we often felt that something was missing,” says YeXin, Duan’s partner in the venture. “The missing piece is a sense of achievement. Though we were well paid at the American

Merck Cuts 
Posted on Aug 01, 2011

As we were wrapping up our annual July vacation, we were shocked to hear about the magnitude of job cuts at Merck. This is on top of the 11,500 jobs Merck cut last year. Even worse, Merck apparently intends to trim headcount to their pre-Shering-Plough days, which translates into (roughly) an additional 41,000 jobs (91,000 currently –

All you need is…guts 
Posted on Jul 11, 2011

Luke Timmerman at Xconomy wrote a provocative piece today entitled The Missing Ingredient in Today’s Biotech: Guts. His thesis is that the industry is so paralyzed by fear and insecurity that it lacks the collective fortitude to take risks, even if they seem delusional. To quote: If the industry–VCs, scientists, entrepreneurs, everybody—can’t get the mojo back, then we

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.